Management of a Patient with 13% Blast Cells

Disease Classification and Initial Assessment

A patient with 13% blast cells should receive treatment based on their specific disease classification, with hypomethylating agents being the recommended therapy for myelodysplastic syndrome with excess blasts or chronic myelomonocytic leukemia with high blast counts, as recommended by the European Hematology Association 1, 2
The 13% blast percentage falls into a critical diagnostic range that could represent either myelodysplastic syndrome with excess blasts (MDS-EB) or chronic myelomonocytic leukemia with high blast count (CMML), according to the World Health Organization classification 3, 1, 2
Initial assessment should include complete blood count with differential, bone marrow aspiration and biopsy with cytogenetics, molecular testing for genetic mutations, and assessment of disease phenotype, as suggested by the National Comprehensive Cancer Network 5, 1, 4

For myelodysplastic CMML with high blast count, first-line therapy is hypomethylating agents (5-azacitidine or decitabine) with supportive care, as recommended by the European Society for Medical Oncology 1, 2
Consider allogeneic stem cell transplantation (allo-SCT) in selected younger patients (<65 years) within clinical trials, according to the European Group for Blood and Marrow Transplantation 1, 2
For patients with early AML features, standard induction chemotherapy may be considered for patients <60 years with good performance status, as suggested by the National Comprehensive Cancer Network 5, 4
For older patients or those with comorbidities, hypomethylating agents are preferred, as recommended by the International Society of Geriatric Oncology 5, 7

Leukocytosis management: if the absolute blast count exceeds 50,000/mcL, rapid cytoreduction with hydroxyurea is recommended to prevent leukostasis complications, as suggested by the American Society of Hematology 5
Transplant eligibility: HLA typing is recommended for patients aged under 65 years to assess transplant eligibility, according to the European Society for Medical Oncology 1, 2
Response assessment: use modified International Working Group response criteria to evaluate treatment efficacy, as recommended by the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia 3

Inappropriate therapy intensity: avoid intensive AML-type induction in older patients or those with significant comorbidities, as this may lead to excess treatment-related mortality, as warned by the National Comprehensive Cancer Network and the European Society for Medical Oncology 5, 7
Neglecting supportive care: always incorporate appropriate supportive measures including transfusion support and infection prophylaxis alongside disease-modifying therapy, as recommended by the European Hematology Association 1, 2